Intuitive Surgical Inc (ISRG) KPIs and segments
Close on Nov 18, 2026Market cap $145.92BP/E 50.9Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Intuitive Surgical · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Intuitive Surgical: 56 chỉ số vận hành, trong đó có Total da Vinci Surgical Procedures Worldwide, Ion Endoluminal Lung Biopsy Procedures Performed và How Often a Surgeon Starts a da Vinci Procedure, lấy từ 181 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product($M) | 2,567 | 2,420 | 2,337 | 2,444 | 2,109 | 2,049 | 1,890 | 2,066 | 1,709 | 1,693 | 1,577 | 1,624 | |
Instruments and accessories($M) | 1,797 | 1,735 | 1,686 | 1,658 | 1,519 | 1,474 | 1,368 | 1,412 | 1,264 | 1,244 | 1,159 | 1,144 | |
Systems($M) | 769 | 685 | 651 | 786 | 590 | 575 | 523 | 655 | 445 | 448 | 418 | 480 | |
Service($M) | 482 | 472 | 434 | 422 | 396 | 391 | 363 | 347 | 329 | 317 | 314 | 304 | |
Product($M) | 1,769 | 1,643 | 1,557 | 1,634 | 1,410 | 1,363 | 1,220 | 1,402 | 1,154 | 1,153 | 1,023 | 1,063 | |
Service($M) | 316 | 318 | 273 | 270 | 253 | 255 | 238 | 240 | 220 | 220 | 223 | 215 | |
Total da Vinci Surgical Procedures Worldwide (Thousands)(M)5 | 906 | 889 | 847 | 849 | 797 | 775 | 732 | 725 | 613 | ||||
Total da Vinci Procedures — Reported YoY Growth (%)(%) | 14.0% | 15.0% | 16.0% | 17.0% | 19.0% | 17.0% | 17.0% | ||||||
Combined Worldwide Procedures (da Vinci + Ion) — Reported YoY Growth (%)(%) | 15.0% | 16.0% | 17.0% | 18.0% | 20.0% | ||||||||
U.S. da Vinci Surgical Procedures (Thousands)(M)1 | 559 | 552 | 528 | 544 | 507 | 495 | 465 | ||||||
U.S. da Vinci Procedures — Reported YoY Growth (%)(%) | 10.0% | 12.0% | 14.0% | 16.0% | 14.0% | 13.0% | |||||||
Outside U.S. (OUS) da Vinci Surgical Procedures (Thousands)(M)1 | 347 | 337 | 319 | 304 | 290 | 280 | 267 | ||||||
OUS da Vinci Procedures — Reported YoY Growth (%)(%) | 20.0% | 20.0% | 19.0% | 24.0% | 23.0% | 24.0% | |||||||
da Vinci SP Single-Port Procedures — Reported YoY Growth (%)(%) | 55.0% | 68.0% | 78.0% | 91.0% | 88.0% | 81.0% | 70.0% | 74.0% | 60.0% | 58.0% | |||
Ion Endoluminal Lung Biopsy Procedures Performed1 | 49,700 | 47,900 | 42,700 | 40,200 | 37,900 | 35,300 | 30,700 | ||||||
Ion Endoluminal Biopsy Procedures — Reported YoY Growth (%)(%) | 31.0% | 36.0% | 39.0% | 44.0% | 52.0% | 52.0% | 58.0% | 73.0% | 82.0% | 90.0% | |||
da Vinci Surgical System Installed Base — Worldwide Total6 | 12,094 | 11,710 | 11,395 | 11,106 | 10,763 | 10,488 | 10,189 | 9,902 | 9,539 | 9,203 | 8,887 | 8,606 | |
U.S. da Vinci Installed Base | 6,807 | 6,615 | 6,477 | 6,364 | 5,807 | 5,111 | |||||||
Europe da Vinci Installed Base | 2,436 | 2,325 | 2,257 | 2,168 | 1,867 | 1,617 | |||||||
Asia da Vinci Installed Base | 2,176 | 2,111 | 2,049 | 1,993 | 1,745 | 1,484 | |||||||
Rest of World da Vinci Installed Base | 675 | 659 | 612 | 581 | 483 | 394 | |||||||
da Vinci SP Single-Port Installed Base | 487 | 445 | 410 | 377 | 343 | 314 | 291 | 273 | 243 | 222 | 201 | 177 | |
da Vinci Installed Base under Operating Lease Arrangements — Total2 | 3,555 | 3,425 | 3,325 | 3,210 | 3,115 | 2,987 | 2,906 | 2,799 | 2,227 | ||||
Fixed-Payment Operating Lease Installed Base (da Vinci) | 1,581 | 1,522 | 1,477 | 1,400 | 1,379 | 1,301 | 1,308 | 1,307 | 1,204 | ||||
Usage-Based Operating Lease Installed Base (da Vinci) | 1,974 | 1,903 | 1,848 | 1,810 | 1,736 | 1,686 | 1,598 | 1,492 | 1,023 | ||||
Ion Endoluminal System Installed Base — Worldwide Total1 | 1,152 | 1,096 | 1,041 | 995 | 954 | 905 | 853 | 805 | 736 | 678 | 604 | 534 | |
Ion Installed Base under Operating Lease Arrangements — Total2 | 411 | 397 | 380 | 360 | 362 | 358 | 334 | 319 | 214 | ||||
Fixed-Payment Operating Lease Installed Base (Ion) | 109 | 110 | 112 | 110 | 123 | 127 | 124 | 126 | 96 | ||||
Usage-Based Operating Lease Installed Base (Ion) | 302 | 287 | 268 | 250 | 239 | 231 | 210 | 193 | 118 | ||||
da Vinci Surgical Systems Placed — Worldwide Total6 | 546 | 468 | 431 | 532 | 427 | 395 | 367 | 493 | 17 | 24 | 13 | 415 | |
da Vinci 5 Fifth-Generation Systems Placed | 315 | 246 | 232 | 303 | 240 | 180 | 147 | 174 | 110 | 70 | 8 | ||
da Vinci SP Single-Port Systems Placed | 42 | 34 | 35 | 30 | 23 | 19 | 30 | 21 | 21 | 24 | 19 | ||
U.S. da Vinci System Placements | 335 | 267 | 226 | 304 | 263 | 216 | 204 | 284 | 219 | 149 | 148 | 209 | |
Outside U.S. (OUS) da Vinci System Placements3 | 211 | 201 | 205 | 228 | 164 | 179 | 163 | 209 | 160 | 192 | 165 | 206 | |
Europe da Vinci System Placements | 115 | 79 | 117 | 118 | 63 | 73 | 88 | 89 | 65 | 71 | 84 | 71 | |
Asia da Vinci System Placements | 78 | 75 | 62 | 88 | 60 | 69 | 52 | 96 | 74 | 95 | 56 | 110 | |
Other Markets da Vinci System Placements | 18 | 47 | 26 | 22 | 41 | 37 | 23 | 24 | 21 | 26 | 25 | 25 | |
da Vinci Unit Placements Involving Trade-In Transactions | 150 | 144 | 119 | 146 | 141 | 83 | 67 | 62 | 51 | ||||
da Vinci System Placements under All Leasing Arrangements2 | 303 | 264 | 256 | 262 | 243 | 199 | 208 | ||||||
da Vinci System Placements under Operating Lease Arrangements3 | 291 | 254 | 243 | 250 | 231 | 193 | 198 | ||||||
Fixed-Payment Operating Lease Placements (da Vinci) | 131 | 123 | 125 | 100 | 116 | 69 | 91 | 82 | 92 | ||||
Usage-Based Operating Lease Placements (da Vinci) | 160 | 131 | 118 | 150 | 115 | 124 | 107 | 140 | 109 | ||||
Operating Lease Share of Total da Vinci Placements (%)(%) | 53.0% | 54.0% | 56.0% | 54.0% | 49.0% | 54.0% | |||||||
da Vinci System Placements under Sales-Type Lease Arrangements | 12 | 10 | 13 | 12 | 12 | 6 | 10 | ||||||
Ion Endoluminal Systems Placed — Worldwide Total3 | 56 | 55 | 52 | 42 | 50 | 54 | 49 | 69 | 44 | ||||
U.S. Ion System Placements | 44 | 42 | 39 | 36 | 41 | 47 | 45 | ||||||
Outside U.S. (OUS) Ion System Placements3 | 12 | 13 | 13 | 6 | 9 | 7 | 4 | ||||||
Europe Ion System Placements | 10 | 9 | 9 | 5 | |||||||||
Asia Ion System Placements | 1 | 2 | 2 | 1 | |||||||||
Other Markets Ion System Placements | 1 | 2 | 2 | 0 | |||||||||
Ion System Placements under All Leasing Arrangements2 | |||||||||||||
Ion System Placements under Operating Lease Arrangements3 | 26 | 31 | 36 | 16 | 17 | 34 | 29 | ||||||
Fixed-Payment Operating Lease Placements (Ion) | 1,581 | 1,522 | 1,477 | 5 | 1,379 | 1,301 | 1,308 | 24 | 14 | ||||
Usage-Based Operating Lease Placements (Ion) | 1,974 | 17 | 1,848 | 11 | 1,736 | 21 | 1,598 | 14 | 15 | ||||
Operating Lease Share of Total Ion Placements (%)(%) | 46.0% | 56.0% | 69.0% | 34.0% | 63.0% | 59.0% | |||||||
Ion System Placements under Sales-Type Lease Arrangements | 2 | 2 | 0 | 5 | 5 | ||||||||
da Vinci Surgical System Average Selling Price — ASP ($M)($M) | 1.61 | 1.59 | 1.74 | 1.68 | 1.60 | 1.50 | 1.62 | 1.59 | 1.51 | 1.44 | 1.38 | 1.42 | |
da Vinci Instruments & Accessories (I&A) Revenue per Procedure ($)($)1 | 1,860 | 1,880 | 1,850 | 1,800 | 1,800 | 1,860 | 1,800 | 1,800 | 1,780 | 1,800 | |||
Ion Endoluminal I&A Revenue per Procedure ($)($) | 2,200 | 2,200 | |||||||||||
Total Recurring Revenue (I&A, Services & Operating Leases) ($M)($M)1 | 2,555 | 2,469 | 2,370 | 2,323 | 2,138 | 2,079 | 1,926 | ||||||
Recurring Revenue as % of Total Revenue (%)(%) | 84.0% | 85.0% | 86.0% | 81.0% | 85.0% | 85.0% | 85.0% | 80.0% | 82.0% | ||||
Operating Lease Revenue Recognized ($M)($M)3 | 275 | 262 | 250 | 242 | 223 | 214 | 195 | 182 | 168 | 157 | 148 | 139 | |
Variable (Usage-Based) Operating Lease Revenue ($M)($M) | 178 | 169 | 157 | 151 | 138 | 130 | 112 | 101 | 87 | 80.1 | 70 | 63.1 | |
Sales-Type Lease Revenue Recognized ($M)($M) | 25.3 | 20.8 | 32.7 | 24.8 | 30.9 | 15.1 | 26.5 | 74.5 | 30.2 | 45.1 | 13.3 | 23.9 | |
Revenue from Customer Purchases of Leased Systems (Lease Buyouts) ($M)($M) | 45 | 56 | 51 | 39 | 22 | 30 | 39 | ||||||
Remaining Performance Obligations (RPO — Unsatisfied Contract Revenue) ($M)($M)3 | 3,800 | 3,400 | 3,300 | 3,000 | 2,880 | 2,810 | 2,670 | 2,620 | 2,520 | 2,370 | 2,340 | 2,290 | |
Revenue Recognized from Beginning Contract Liability Balance ($M)($M) | 97 | 147 | 234 | 44 | 91 | 126 | 198 | 34 | 81 | 118 | 189 | 24 | |
Contract Assets ($M)($M) | 33.8 | 27.2 | 20.3 | 15.3 | 18.2 | 20.9 | 19.9 | 13.9 | 17.7 | 16.7 | 17.4 | 20.2 | |
Contract Liabilities — Total ($M)($M)2 | 669 | 662 | 664 | 598 | 571 | 572 | 560 | 523 | 486 | 477 | 488 | 492 | |
Deferred Revenue — Current ($M)($M) | 541 | 549 | 560 | 507 | 491 | 500 | 496 | 469 | 426 | 434 | 438 | 446 | |
Deferred Revenue — Non-Current ($M)($M) | 128 | 113 | 104 | 91.4 | 79.4 | 71.8 | 63.6 | 54.1 | 59.6 | 43.5 | 50.2 | 45.6 | |
Foreign-Currency-Denominated Revenue as % of Total Revenue (%)(%) | 27.0% | 27.0% | 29.0% | 24.0% | 26.0% | 25.0% | |||||||
Total Consolidated Revenue ($M)($M)5 | 3,049 | 2,892 | 2,771 | 2,866 | 2,505 | 2,440 | 2,253 | 2,414 | 2,038 | 2,010 | 1,891 | 1,928 | |
Instruments & Accessories Revenue — Worldwide ($M)2 | |||||||||||||
Instruments & Accessories Revenue — U.S. ($M)($M) | 1,248 | 1,180 | 1,122 | 1,160 | 1,062 | 1,017 | 964 | 1,008 | 905 | 891 | 822 | 819 | |
Instruments & Accessories Revenue — Outside U.S. (OUS) ($M)($M) | 550 | 555 | 565 | 498 | 457 | 457 | 404 | 404 | 359 | 353 | 337 | 324 | |
Systems Revenue — Worldwide ($M)2 | |||||||||||||
Systems Revenue — U.S. ($M)($M) | 506 | 442 | 380 | 494 | 398 | 354 | 336 | 420 | 265 | 224 | 213 | 238 | |
Systems Revenue — Outside U.S. (OUS) ($M)($M) | 264 | 243 | 271 | 292 | 193 | 221 | 187 | 234 | 180 | 224 | 206 | 242 | |
Services Revenue — Worldwide ($M)2 | |||||||||||||
Services Revenue — U.S. ($M)($M) | 310 | 311 | 282 | 276 | 258 | 258 | 239 | 224 | 209 | 204 | 204 | 199 | |
Services Revenue — Outside U.S. (OUS) ($M)($M) | 173 | 162 | 152 | 146 | 138 | 133 | 125 | 123 | 120 | 114 | 110 | 106 | |
Total U.S. Revenue ($M)($M)1 | 2,063 | 1,933 | 1,783 | 1,931 | 1,718 | 1,629 | 1,538 | 1,652 | 1,379 | 1,319 | 1,239 | 1,256 | |
U.S. Share of Total Revenue (%)(%) | 68.0% | 67.0% | 64.0% | 69.0% | 67.0% | 68.0% | 68.0% | 66.0% | 66.0% | ||||
Total Outside U.S. (OUS) Revenue ($M)($M)1 | 986 | 959 | 988 | 936 | 788 | 811 | 715 | 761 | 659 | 691 | 652 | 672 | |
Outside U.S. (OUS) Share of Total Revenue (%)(%) | 32.0% | 33.0% | 36.0% | 31.0% | 33.0% | 32.0% | 32.0% | 34.0% | 34.0% | ||||
Product Gross Profit ($M)($M)1 | 1,769 | 1,643 | 1,557 | 1,410 | 1,363 | 1,220 | |||||||
Product Gross Profit Margin (%)(%) | 68.9% | 67.9% | 66.6% | 66.8% | 66.5% | 64.5% | |||||||
Service Gross Profit ($M)($M)1 | 316 | 318 | 273 | 253 | 255 | 238 | |||||||
Service Gross Profit Margin (%)(%) | 65.4% | 67.2% | 63.0% | 63.8% | 65.3% | 65.6% | |||||||
Non-GAAP Gross Profit ($M)($M)2 | 2,130 | 2,024 | 1,879 | 1,942 | 1,704 | 1,657 | 1,497 | 1,678 | 1,408 | 1,406 | 1,279 | 1,311 | |
Non-GAAP Gross Profit Margin (%)(%) | 69.9% | 70.0% | 67.8% | 67.6% | 68.0% | 67.9% | 66.4% | ||||||
GAAP Gross Profit Margin (%)(%) | 68.4% | 67.8% | 66.1% | 66.0% | 66.4% | 66.3% | 64.7% | ||||||
Non-GAAP Income from Operations ($M)($M) | 1,270 | 1,218 | 1,077 | 1,070 | 976 | 947 | 768 | 928 | 755 | 754 | 630 | 621 | |
Non-GAAP Net Income Attributable to Intuitive Surgical, Inc. ($M)($M)1 | 1,055 | 1,002 | 901 | 914 | 867 | 798 | 662 | 805 | 669 | 641 | 541 | 574 | |
Non-GAAP Diluted Net Income per Share ($)(€) | 3 | 2.80 | 2.50 | 2.53 | 2.40 | 2.19 | 1.81 | 2.21 | 1.84 | 1.78 | 1.50 | 1.60 | |
Share-Based Compensation Expense — Total Recognized ($M)($M)4 | 216 | 213 | 213 | 207 | 206 | 200 | 190 | 180 | 176 | 176 | 156 | 152 | |
Share-Based Compensation — Total Cost of Revenue ($M)($M)2 | 38.5 | 38 | 38.6 | 37.6 | 40.3 | 38.9 | 38.4 | 35.3 | 32.8 | 31.2 | 29.7 | 30 | |
Share-Based Compensation — Cost of Product Revenue ($M)($M) | 28.4 | 28.8 | 29.3 | 28.7 | 31.5 | 30.3 | 30.2 | 27.3 | 24.9 | 23.6 | 22.7 | 23.1 | |
Share-Based Compensation — Cost of Service Revenue ($M)($M) | 10.1 | 9.20 | 9.30 | 8.90 | 8.80 | 8.60 | 8.20 | 8 | 7.90 | 7.60 | 7 | 6.90 | |
Share-Based Compensation — Research & Development ($M)($M) | 87.7 | 86.7 | 82 | 79.8 | 77.6 | 74.7 | 69 | 65.9 | 65.4 | 65.6 | 57.7 | 54.1 | |
Share-Based Compensation — Selling, General & Administrative ($M)($M) | 89.5 | 88.1 | 92.7 | 89.8 | 88.1 | 86.3 | 82.3 | 79.1 | 77.6 | 79.6 | 68.2 | 68.2 | |
Income Tax Benefit Recognized for Share-Based Compensation ($M)($M) | 43 | 43 | 42.7 | 42.5 | 42.5 | 39.3 | 37 | 32.9 | 36.9 | 36.1 | 32.4 | 32.2 | |
Total Inventories, Net ($M)($M)3 | 2,128 | 2,029 | 1,945 | 1,840 | 1,782 | 1,667 | 1,554 | 1,487 | 1,482 | 1,384 | 1,299 | 1,221 | |
Raw Materials Inventory ($M)($M) | 652 | 608 | 591 | 561 | 531 | 525 | 550 | 564 | 523 | 484 | 470 | 455 | |
Work-in-Process Inventory ($M)($M) | 333 | 332 | 307 | 288 | 225 | 231 | 230 | 206 | 215 | 183 | 181 | 160 | |
Finished Goods Inventory ($M)($M) | 1,143 | 1,088 | 1,047 | 991 | 1,026 | 911 | 774 | 718 | 744 | 718 | 648 | 606 | |
Accounts Receivable, Net ($M)($M)3 | 1,721 | 1,673 | 1,596 | 1,527 | 1,260 | 1,269 | 1,222 | 1,225 | 1,153 | 1,109 | 1,128 | 1,130 | |
Trade Accounts Receivable, Net ($M)($M) | 1,472 | 1,433 | 1,391 | 1,358 | 1,120 | 1,132 | 1,091 | 1,117 | 985 | 1,003 | 1,029 | 1,042 | |
Unbilled Accounts Receivable ($M)($M) | 278 | 269 | 237 | 196 | 165 | 160 | 155 | 139 | 192 | 124 | 116 | 105 | |
Reserve for Sales Returns ($M)($M) | 28.5 | 28.9 | 32.7 | 26.7 | 24.9 | 22.9 | 24 | 30.5 | 23.6 | 17.9 | 16.2 | 17 | |
Net Investment in Sales-Type Leases — Total ($M)($M)7 | 331 | 337 | 366 | 303 | 330 | 338 | 358 | 380 | 350 | 354 | 344 | 372 | |
Gross Sales-Type Lease Receivables ($M)($M) | 358 | 368 | 397 | 318 | 345 | 352 | 372 | 393 | 363 | 366 | 357 | 385 | |
Deferred Profit / Unearned Income on Sales-Type Leases ($M)($M) | 27.1 | 30.4 | 30.9 | 14.7 | 14.8 | 13.7 | 14.2 | 13.9 | 12.7 | 12.8 | 12.2 | 12.9 | |
Current Portion of Net Investment in Sales-Type Leases ($M)($M) | 104 | 102 | 116 | 101 | 124 | 125 | 128 | 131 | 137 | 134 | 133 | 137 | |
Sales-Type Lease Net Investment — High Internal Credit Quality ($M)($M) | 154 | 149 | 192 | 160 | 175 | 174 | 175 | 184 | 161 | 179 | 179 | 201 | |
Sales-Type Lease Net Investment — Moderate Internal Credit Quality ($M)($M) | 175 | 185 | 170 | 136 | 147 | 154 | 176 | 189 | 183 | 164 | 156 | 160 | |
Sales-Type Lease Net Investment — Low Internal Credit Quality ($M)($M) | 2.60 | 2.90 | 4.20 | 7.40 | 8.50 | 9.90 | 6.80 | 5.70 | 5.80 | 11.2 | 9.40 | 10.6 | |
Undiscounted Future Sales-Type Lease Payments Receivable — Total ($M)($M)4 | 358 | 368 | 397 | 318 | 345 | 352 | 372 | 393 | 363 | 366 | 357 | 385 | |
Property, Plant & Equipment, Net ($M)($M)2 | 5,676 | 5,552 | 5,448 | 5,342 | 5,151 | 4,985 | 4,799 | 4,647 | 4,433 | 4,117 | 3,800 | 3,538 | |
Capital Expenditures Incurred but Not Yet Paid ($M)($M) | 13.3 | 3.60 | 65.2 | -9.30 | 5.10 | -23 | 97.8 | -118 | 10.7 | 6.30 | 178 | 18.5 | |
U.S. Share of Total Long-Lived Assets (%)(%) | 80.0% | 80.0% | 81.0% | 81.0% | 81.0% | 83.0% | |||||||
Goodwill ($M)($M)1 | 558 | 581 | 613 | 370 | 348 | 349 | 348 | 348 | 348 | 348 | 348 | 349 | |
Intangible Assets, Net ($M)($M)5 | 197 | 198 | 174 | 17.1 | 23 | ||||||||
Finite-Lived Intangibles, Net — Customer Relationships ($M)($M) | 175 | 180 | 144 | 1.10 | 2.10 | 3.20 | 3.90 | 5 | 6.20 | 7.10 | 8.20 | 9.60 | |
Finite-Lived Intangibles, Net — Distribution Rights ($M)($M) | 4.90 | 5.20 | 15.6 | 0 | 0 | 0 | 0.10 | 0.10 | 0.30 | 0.60 | 1.10 | 1.60 | |
Finite-Lived Intangibles, Net — Technology-Based ($M)($M) | 11.2 | 6.50 | 8.20 | 10 | 12.4 | 14.7 | 15.6 | 17.9 | 18.8 | 21 | 24.5 | 27.9 | |
Indefinite-Lived IPR&D Intangible Assets ($M)($M) | 6 | 6 | 6 | 6 | 0 | ||||||||
Amortization Expense of Intangible Assets ($M)($M) | 9.30 | 24 | 7.10 | 3.30 | 3.30 | 3.20 | 3.40 | 3.10 | 3.50 | 5 | 5.10 | 5.10 | |
Common Stock Repurchased — Total Value ($M)($M)3 | 2,940 | 379 | 1,128 | 200 | 1,920 | 181 | 0 | 0 | 0 | 0 | 0 | 66.3 | |
Common Stock Repurchased — Shares (Millions)(M) | 7.80 | 0.90 | 2.30 | 0.40 | 4 | 0.30 | 0 | 0 | 0 | 0 | 0 | 0.20 | |
Weighted-Average Share Repurchase Price ($)(€) | 377 | 439 | 490 | 480 | 518 | 0 | 0 | 0 | 0 | ||||
Remaining Share Repurchase Authorization ($M)($M) | 1,800 | 4,700 | 600 | 1,700 | 1,900 | 3,800 | 1,100 | 1,100 | 1,100 | 1,100 | 1,100 | 1,100 | |
Income Before Taxes — Consolidated ($M)($M) | 668 | 1,055 | 940 | 956 | 855 | 832 | 669 | 810 | 671 | 655 | 539 | 516 | |
Intuitive-Fosun Joint Venture (China, 40% NCI) — Net Income (Loss) Attributable to Noncontrolling Interest ($M)($M)1 | 1.60 | 5.10 | 4.50 | 4.70 | 4.80 | 5.80 | 5.30 | 2.30 | 5.50 | 4.60 | 2.50 | 4.50 | |
Intuitive-Fosun Joint Venture (China, 40% NCI) — Noncontrolling Interest Equity Balance ($M)($M) | 132 | 129 | 123 | 118 | 112 | 107 | 101 | 95.9 | 94.2 | 88.2 | 83.8 | 89.7 | |
ab medica / Abex / Excelencia Robótica Acquisition (Italy, Spain & Portugal) — Purchase Consideration ($M)4 | |||||||||||||
ab medica / Abex Acquisition — Goodwill Recognized ($M)($M) | 196 | ||||||||||||
ab medica / Abex Acquisition — Intangible Assets Recognized ($M)($M) | 281 | ||||||||||||
ab medica / Abex Acquisition — Property, Plant & Equipment Acquired ($M)($M) | 60.6 | ||||||||||||
ab medica / Abex Acquisition — Net Assets Acquired ($M)($M) | 550 | ||||||||||||
Antitrust Class Action Litigation Settlement Charge ($M)($M)1 | 450 | 0 | |||||||||||
Accrued Antitrust Litigation Settlement Liability ($M)($M) | 450 | ||||||||||||
Intuitive Surgical — FDA 510(k) Premarket Clearances Granted3 | 4 | 1 | 4 | 4 | 10 | 5 | 2 | 4 | 8 | 3 | 1 | 2 | |
U.S. MedTech Industry Total — FDA 510(k) Premarket Clearances | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
Intuitive Surgical — FDA Premarket Approvals (PMA & Supplements) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
U.S. MedTech Industry Total — FDA Premarket Approvals (PMA & Supplements) | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
Intuitive Surgical — FDA MAUDE Medical Device Adverse Event Reports (Total)5 | 9,784 | 10,712 | 20,202 | 10,239 | 11,983 | 16,010 | 12,287 | 3,956 | 3,562 | 3,356 | 3,096 | 2,870 | |
Intuitive Surgical — FDA MAUDE Device Malfunction Reports | 8,856 | 9,887 | 19,491 | 9,521 | 11,348 | 15,311 | 11,730 | 3,186 | 2,913 | 2,747 | 2,555 | 2,289 | |
Intuitive Surgical — FDA MAUDE Patient Injury Reports | 812 | 793 | 677 | 678 | 597 | 658 | 532 | 729 | 609 | 584 | 523 | 552 | |
Intuitive Surgical — FDA MAUDE Death Reports | 40 | 32 | 34 | 39 | 37 | 39 | 23 | 38 | 39 | 22 | 16 | 26 | |
U.S. MedTech Industry Total — FDA MAUDE Adverse Event Reports | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
Intuitive Surgical — FDA Medical Device Recalls | 1 | 4 | 11 | 1 | 0 | 0 | 40 | 0 | 1 | 1 | 0 | 1 | |
ClinicalTrials.gov — Cumulative Registered Clinical Studies (Intuitive Surgical)1 | |||||||||||||
ClinicalTrials.gov — New Studies Started in Period | 2 | 2 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 3 | ||
U.S. Producer Price Index (PPI) — Surgical & Medical Instrument Manufacturing (PCU339112339112)(×)2 | 163.40 | 162.90 | 161.70 | 159.60 | 157.80 | 156.90 | 157.10 | 155.20 | 154.40 | 154.10 | 153.60 | 151.00 | |
U.S. PPI — Surgical Appliance & Supplies Manufacturing (PCU339113339113)(×) | 269.30 | 263.80 | 253.80 | 251.40 | 249.60 | 249.50 | 248.70 | 245.40 | 245.10 | 243.70 | 240.10 | 238.50 | |
U.S. PPI — Electromedical & Electrotherapeutic Apparatus Manufacturing (PCU334510334510)(×) | 92.80 | 92.10 | 92.00 | 91.60 | 90.70 | 90.30 | 90.10 | 89.50 | 89.30 | 88.40 | 88.30 | 87.80 | |
U.S. Consumer Price Index (CPI-U) — Medical Care Services (CUSR0000SAM2)(×)2 | 654.70 | 650.90 | 647.60 | 638.40 | 630.60 | 623.40 | 619.60 | 613.00 | 611.40 | 605.80 | 597.90 | ||
U.S. CPI-U — Medical Care Commodities (CUSR0000SAM1)(×) | 404.90 | 410.40 | 416.80 | 417.00 | 416.50 | 416.00 | 412.60 | 415.90 | 414.50 | 408.30 | 410.10 | ||
U.S. Census Bureau QSS — U.S. Hospitals Quarterly Revenue (REV622TAXABL144QNSA) ($M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Total Revenue ($M)($M)1 | 3,049 | 2,892 | 2,771 | 2,866 | 2,505 | 2,440 | 2,253 | 2,414 | 2,038 | 2,010 | 1,891 | 1,928 | |
Gross Profit ($M)($M) | 2,084 | 1,960 | 1,831 | 1,904 | 1,662 | 1,618 | 1,458 | 1,642 | 1,374 | 1,373 | 1,245 | 1,277 | |
Operating Income ($M)($M)3 | 593 | 972 | 855 | 864 | 760 | 743 | 578 | 735 | 577 | 567 | 469 | 450 | |
Total Operating Expenses ($M)($M) | 1,492 | 989 | 975 | 1,040 | 903 | 875 | 880 | 907 | 797 | 805 | 776 | 827 | |
Research & Development Expense ($M)($M) | 408 | 371 | 362 | 353 | 329 | 313 | 316 | 295 | 286 | 280 | 285 | 260 | |
Selling, General & Administrative Expense ($M)($M) | 633 | 618 | 613 | 687 | 573 | 561 | 563 | 613 | 511 | 525 | 492 | 567 | |
Net Income Attributable to Intuitive Surgical, Inc. ($M)($M)8 | 523 | 818 | 822 | 795 | 704 | 658 | 698 | 686 | 565 | 527 | 545 | 606 | |
Interest & Other Non-Operating Income, Net ($M)($M) | 75.8 | 82.7 | 85.1 | 91.3 | 95.5 | 88.7 | 90.4 | 74.9 | 93.7 | 87.2 | 69.1 | 65.7 | |
Income Before Taxes ($M)($M) | 668 | 1,055 | 940 | 956 | 855 | 832 | 669 | 810 | 671 | 655 | 539 | 516 | |
Income Tax Expense ($M)($M) | 144 | 231 | 114 | 156 | 146 | 168 | -35.2 | 122 | 100 | 123 | -8.90 | -94.8 | |
Net Income (Loss) Attributable to Noncontrolling Interest ($M)($M) | 1.60 | 5.10 | 4.50 | 4.70 | 4.80 | 5.80 | 5.30 | 2.30 | 5.50 | 4.60 | 2.50 | 4.50 | |
Basic Earnings per Share ($)(€) | 1.50 | 2.31 | 2.31 | 1.98 | 1.84 | 1.95 | 1.59 | 1.48 | 1.54 | ||||
Diluted Earnings per Share ($)(€) | 1.49 | 2.29 | 2.28 | 1.95 | 1.81 | 1.92 | 1.56 | 1.46 | 1.51 | ||||
Weighted-Average Basic Shares (Millions)(M) | 349 | 354 | 355 | 357 | 359 | 358 | 356 | 355 | 354 | ||||
Weighted-Average Diluted Shares (Millions)(M) | 352 | 357 | 360 | 362 | 364 | 365 | 363 | 361 | 361 | ||||
Total Assets ($M)2 | |||||||||||||
Cash & Cash Equivalents ($M)($M) | 2,978 | 2,760 | 2,007 | 3,368 | 2,807 | 3,447 | 2,617 | 2,062 | 2,446 | 3,067 | 2,867 | 2,770 | |
Prepaid Expenses & Other Current Assets ($M)($M) | 536 | 625 | 752 | 477 | 575 | 483 | 371 | 385 | 349 | 404 | 405 | 314 | |
Operating Cash Flow ($M)($M)2 | 1,224 | 1,061 | 912 | 893 | 841 | 715 | 582 | 823 | 707 | 621 | 265 | 228 | |
Capital Expenditures ($M)($M) | 113 | 113 | 103 | 163 | 105 | 155 | 117 | 312 | 248 | 309 | 242 | 436 | |
Investing Cash Flow ($M)($M) | 1,898 | -26.6 | -915 | -209 | 401 | 261 | 214 | -1,264 | -1,413 | -467 | -129 | -1,044 | |
1 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core KPI Drivers (Groups 1–4): Surgical & diagnostic procedure volumes (da Vinci by region & clinical specialty, Ion endoluminal lung biopsy, da Vinci SP growth), Installed Base by platform/region/lease model, System Placements by generation/console/region/lease model, and Unit Economics (System ASP, I&A revenue per procedure, Recurring Revenue, Operating vs. Sales-Type Lease revenue, Lease Buyouts & RPO).
- Standalone / Parent-Only Assessment (Step 3 & Step 4): Intuitive Surgical, Inc. files under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary & JV operations are instead captured directly from explicit disclosures in Group 10: Intuitive-Fosun Joint Venture in China (40% noncontrolling interest net income & equity) and the European direct distribution acquisition of ab medica, Abex & Excelencia Robótica (closed March 2, 2026).
- Period Splitting (Step 4): Q4 values for 10-K/10-Q cumulative tables and cash flow statement quarters (Q2–Q4) are derived strictly via FY − 9M or YTD − prior YTD.
Không hiện vì thiếu các kỳ gần đây (13)
- Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — U.S. Federal ($M)
- Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — U.S. State ($M)
- Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — Switzerland ($M)
- Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M) › Cash Taxes Paid — Other Foreign Jurisdictions ($M)
- Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return › Income Before Taxes — Consolidated ($M) › Cash Income Taxes Paid, Net ($M)
- Cumulative Peer-Reviewed Scientific Articles Referencing Intuitive Technologies (21,000+ to 43,000+) — Disclosed as lower-bound floor ('21,000+', '24,000+', '29,000+', '34,000+', '38,000+', 'more than 43,000') in ESG Reports 2019–2024; excluded per Step 5 rule against bound/floor figures.
- New Peer-Reviewed Scientific Articles Published in Year (2,800+ to 4,000+) — Disclosed as lower-bound floor ('2,800+', '3,000+', '3,700+', '3,300+', '4,000+') in ESG Reports 2019–2024; excluded per Step 5 rule against bound/floor figures.
- Cumulative Surgeons Trained on da Vinci Systems in U.S. & OUS (32,800+ to 89,500+) — Disclosed as lower-bound floor ('32,800+', '35,000+', '40,400+', '76,000+') in ESG Reports 2019–2023; excluded per Step 5 rule against bound/floor figures.
- Active Patents Granted (2,900+ to 5,400) & Pending Patent Applications (1,900+ to 2,500) — Disclosed as lower-bound floor ('2,900+', '3,400+', '4,200+', '4,300+', '4,800+') in ESG Reports 2019–2023; excluded per Step 5 rule against bound/floor figures.
- Cumulative da Vinci Procedures Performed Since Inception (7.2M+ to 16.94M+) — Disclosed as lower-bound floor ('7.2 million+', '8.5 million+', '10 million+', '14.2 million+', 'nearly 17 million') in ESG & Annual Reports; excluded per Step 5 rule against bound/floor figures.
- Global Training Sessions (6,500+ to 9,000+), Active Proctors (1,000+ to 1,400+) & Portal Users (4,100+ to 17,000+) — Disclosed with '+' floor modifier in ESG Reports 2021–2023; excluded per Step 5 rule against bound/floor figures.
- System Service Uptime (>99%) & QMS / Compliance Training Completion Rate (>98%) — Disclosed with '>' inequality modifier ('>99%', '>98%', '>88%') in ESG Reports 2021–2023; excluded per Step 5 rule against bound/floor figures.
- Quarterly da Vinci System Placements in Japan & China (Earnings Call Transcripts) — Disclosed in Q1 2026 and Q3 2023–Q4 2025 earnings call transcripts, but Q2 2026 and Q3 2026 transcripts did not state exact Japan/China unit counts (lacks 3 consecutive latest quarters FY2026Q1–Q3 per Step 5).
Dữ liệu cập nhật 2026-10-28.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Surgical & Diagnostic Procedures & System Utilization (Key Chính — Core Driver)
Installed Base by Platform, Region & Lease Structure (Key Chính — Core Driver)
System Placements by Platform, Region, Model & Lease Structure (Key Chính — Core Driver)
Unit Economics, Recurring Revenue, Leasing & RPO (Core Driver)
- da Vinci Surgical System Average Selling Price — ASP ($M) ($M)31 kỳ
- da Vinci Instruments & Accessories (I&A) Revenue per Procedure ($) ($)12 kỳ
- Total Recurring Revenue (I&A, Services & Operating Leases) ($M) ($M)7 kỳ
- Operating Lease Revenue Recognized ($M) ($M)35 kỳ
- Remaining Performance Obligations (RPO — Unsatisfied Contract Revenue) ($M) ($M)35 kỳ
- Foreign-Currency-Denominated Revenue as % of Total Revenue (%) (%)16 kỳ
Revenue Disaggregation (Product Category × Geography — U.S. vs. OUS)
Product vs. Service Gross Profit, Non-GAAP Reconciliation & Share-Based Compensation
Working Capital (Inventory by Stage), Lease Receivables, Leased Systems, PP&E & Intangibles
- Total Inventories, Net ($M) ($M)47 kỳ
- Accounts Receivable, Net ($M) ($M)47 kỳ
- Net Investment in Sales-Type Leases — Total ($M) ($M)31 kỳ
- Systems under Operating Leases — Gross Carrying Amount in PP&E ($M) ($M)11 kỳ
- Property, Plant & Equipment, Net ($M) ($M)47 kỳ
- Goodwill ($M) ($M)47 kỳ
- Lessee Operating Lease Right-of-Use (ROU) Assets ($M) ($M)7 kỳ
Workforce, Facilities, Supply Chain (Form SD 3TG), Governance (DEF 14A), Taxes & Capital Return
- Total Full-Time Employees5 kỳ
- Owned Facility Space — Sunnyvale, California HQ (Million Sq. Ft.) (triệu ft²)11 kỳ
- Form SD — 3TG Conflict Minerals In-Scope Supplier Response Rate (%) (%)11 kỳ
- CEO to Median Employee Pay Ratio (x:1) (×)0 kỳ
- Common Stock Repurchased — Total Value ($M) ($M)33 kỳ
- Unconditional Purchase Commitments to Suppliers ($M) ($M)11 kỳ
- Income Before Taxes — Consolidated ($M) ($M)23 kỳ
Environmental Sustainability (Scope 1–3 GHG Inventory), Safety & Workforce Diversity (ESG Reports)
- Total Corporate Carbon Footprint — Combined Scope 1, 2 & 3 GHG Emissions (MT CO2e)4 kỳ
- Global Female Workforce Representation (%) (%)6 kỳ
- U.S. People of Color Workforce Representation (%) (%)6 kỳ
- North America Manufacturing Total Recordable Incident Rate (TRIR per 100 Employees) (×)4 kỳ
- Genesis Customer Analytics & OR Efficiency Engagements Performed4 kỳ
- Supply Chain Spend Receiving Supplier Scorecard Assessments (%) (%)5 kỳ
- Employee Volunteer Hours Donated3 kỳ
Subsidiaries, Joint Ventures (Intuitive-Fosun China JV), M&A & Litigation
- Intuitive-Fosun Joint Venture (China, 40% NCI) — Net Income (Loss) Attributable to Noncontrolling Interest ($M) ($M)39 kỳ
- ab medica / Abex / Excelencia Robótica Acquisition (Italy, Spain & Portugal) — Purchase Consideration ($M) ($M)0 kỳ
- Antitrust Class Action Litigation Settlement Charge ($M) ($M)2 kỳ
External Regulatory & MedTech Industry Benchmarks (openFDA, ClinicalTrials.gov, FRED)
- Intuitive Surgical — FDA 510(k) Premarket Clearances Granted153 kỳ
- Intuitive Surgical — FDA MAUDE Medical Device Adverse Event Reports (Total)153 kỳ
- ClinicalTrials.gov — Cumulative Registered Clinical Studies (Intuitive Surgical)12 kỳ
- U.S. Producer Price Index (PPI) — Surgical & Medical Instrument Manufacturing (PCU339112339112) (×)141 kỳ
- U.S. Consumer Price Index (CPI-U) — Medical Care Services (CUSR0000SAM2) (×)140 kỳ
Consolidated Financial Statements & Product Segment Reference (Postgres DB + FY2026Q3 XBRL)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Intuitive Surgical
- SEC Filing (0001035267-26-000071) ↗
- SEC Filing (0001035267-26-000010) ↗
- Intuitive Surgical 2024 ESG / Sustainability Report ↗
- Form 10-K (filed 2026-02-03) ↗
- SEC Filing (0001035267-26-000067) ↗
- SEC Filing (0001035267-26-000006) ↗
- Intuitive Surgical 2023 ESG / Sustainability Report ↗
- Intuitive Surgical 2026Q3 Earnings Call Transcript (The Motley Fool) ↗
- SEC Filing (0001035267-26-000003) ↗
- SEC Filing (0001035267-26-000039) ↗
See a number that looks wrong?